[What would you do with a patient with non-valvular atrial fibrillation treated with direct-acting oral anticoagulants who had to undergo gastroscopy or colonoscopy?]
In Spain, approximately 25% of patients anticoagulated due to non-valvular atrial fibrillation use a direct-acting anticoagulant (DOAC). It is foreseeable that most of them at some point in their lives should undergo invasive procedures or surgical treatments. This makes the management of DOAC in these situations essential in order to perform the procedure with maximum safety and minimise the risk to the maximum of haemorrhage and thrombosis. The management of this situation is based on the evaluation of the haemorrhagic risk of the patient, and the procedure to be performed, the risk of thromboembolism, and renal function. The pharmacokinetic characteristics of the DOAC also should be taken into account, especially its half-life, the degree of renal elimination and its peak action.